Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
0(0%)
Results Posted
14%(1 trials)

Phase Distribution

Ph phase_2
2
22%
Ph not_applicable
6
67%
Ph phase_1
1
11%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
2(22.2%)
N/ANon-phased studies
6(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(7)
Other(2)

Detailed Status

Completed7
unknown2

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (11.1%)
Phase 22 (22.2%)
N/A6 (66.7%)

Trials by Status

unknown222%
completed778%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_2

Memory and Antioxidants in Vascular Impairment Trial

NCT03306979
completednot_applicable

Drug Nephrotoxicity Amelioration by N-acetylcysteine

NCT06122311
unknownnot_applicable

Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular Carcinoma Following Transarterial Chemoembolization.

NCT06039280
completednot_applicable

N-acetylcysteine Reduces Acetaldehyde Levels in Binge Alcohol Drinking

NCT05911282
unknownphase_2

Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy

NCT04531163
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03306979Phase 2

Memory and Antioxidants in Vascular Impairment Trial

Completed
NCT06122311Not Applicable

Drug Nephrotoxicity Amelioration by N-acetylcysteine

Completed
NCT06039280Not Applicable

Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular Carcinoma Following Transarterial Chemoembolization.

Unknown
NCT05911282Not Applicable

N-acetylcysteine Reduces Acetaldehyde Levels in Binge Alcohol Drinking

Completed
NCT04531163Phase 2

Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy

Unknown
NCT01381354Phase 1

Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)

Completed
NCT03400709Not Applicable

Protective Role of N-acetylcisteine From Cisplatin-induced Ototoxicity in Patients With Head and Neck Cancer

Completed
NCT00353340Not Applicable

Prevention of Contrast Nephropathy by Sodium Bicarbonate Versus Sodium Chloride and N-acetylcysteine

Completed
NCT00564642Not Applicable

Investigation of the Effect of N Acetylcysteine Against Anti-Tuberculosis Drugs Induced Liver Toxicity

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9